| |
Patients
|
Reference value
|
|---|
|
Age (yr) b
|
54.2 ± 10.6
| |
|
Male/Female (ratio)
|
14/16 (0.47)
| |
|
BMI (kg/m2) b
|
23.7 ± 2.7
|
18.5 - 25
|
|
ALT (IU/L) a
|
47.5 (17–167)
|
8 - 42
|
|
γGTP (IU/L) a
|
41 (13–152)
|
10 - 47
|
|
ChE (IU/L) b
|
312.9 ± 88.2
|
185 - 431
|
|
Fasting plasma glucose (mg/dL) b
|
95.5 ± 9.7
|
70 - 109
|
|
Insulin (μIU/mL) a
|
8.7 (4.5 - 20.4)
|
1.84 - 12.2
|
|
HOMA-IR a
|
2.0 (1.2 - 5.1)
| |
|
HOMA-IR > 2.5 (%)
|
9 (30)
| |
|
Triglyceride (mg/dL) b
|
91.4 ± 31.1
|
30 - 149
|
|
Total cholesterol (mg/dL) b
|
175.2 ± 25.4
|
129 - 219
|
|
Acylcarnitine (μmol/L) a
|
9.25 (5.7 - 21.1)
|
6 - 23
|
|
HCV RNA (LogIU/mL) b
|
6.1 ± 0.9
| |
|
HCV core antigen (fmol/L) a
|
6505 (<20–23200)
| |
|
HCV Genotype
|
1b / 2a / 2b
|
20 / 6 / 4
| |
|
Inflammation
|
A0 / A1 / A2 / A3
|
0 / 15 / 10 / 0
| |
|
Fibrosis
|
F0 / F1 / F2 / F3 / F4
|
0 / 15 / 7 / 3 / 0
| |
|
Steatosis
|
G0 / G1 / G2 / G3
|
6 /18 / 1 / 0
| |
- BMI, body mass index; ALT, alanine aminotransferase; γGTP, gamma-glutamyltranspeptidase; ChE, cholinesterase; HOMA-IR, homeostasis model assessment of insulin resistance.
- Data are amedians (min-max), bthe means ± standard deviation.
